---
title: "Wegovy (semaglutide), all indications: Safety questions"
description: "Safety questions on Wegovy (semaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Can Wegovy cause severe stomach side effects? Can Wegovy be used with severe gastroparesis? Does Wegovy increase heart rate? Do antibodies to Wegovy affect how well it works? 10 further questions follow. 14 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/wegovy/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide), all indications: Safety questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)

## Warnings

<a id="wegovy-severe-gi-gastroparesis"></a>

### Can Wegovy cause severe stomach side effects?

> “Use of WEGOVY<sup>®</sup> has been associated with gastrointestinal 
> adverse reactions, sometimes severe [see Adverse Reactions (6)]. In 
> clinical trials for adults for weight reduction, severe gastrointestinal 
> adverse reactions were reported more frequently among patients 
> receiving WEGOVY<sup>®</sup> than placebo. Severe gastrointestinal adverse 
> reactions were reported in 4.1% and 0.9% of WEGOVY<sup>®</sup> injection 
> and placebo-treated patients, respectively, and in 2% of WEGOVY<sup>®</sup> 
> tablet-treated and 0% of placebo-treated patients, respectively. 
> Severe gastrointestinal adverse reactions have also been reported 
> postmarketing with GLP-1 receptor agonists.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

> “Gastrointestinal Disorders: acute pancreatitis and necrotizing 
> pancreatitis, sometimes resulting in death; ileus, intestinal 
> obstruction, severe constipation including fecal impaction”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-gastroparesis"></a>

### Can Wegovy be used with severe gastroparesis?

> “WEGOVY<sup>®</sup> is not recommended in patients with severe 
> gastroparesis.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-heart-rate"></a>

### Does Wegovy increase heart rate?

> “Treatment with WEGOVY<sup>®</sup> was associated with increases in resting 
> heart rate. Mean increases in resting heart rate of 1 to 4 beats per 
> minute (bpm) were observed in WEGOVY<sup>®</sup> injection-treated adult 
> patients compared to placebo in clinical trials for weight reduction. 
> More adult patients treated with WEGOVY<sup>®</sup> injection compared with 
> placebo had maximum changes from baseline at any visit of 10 to 
> 19 bpm (41% versus 34%, respectively) and 20 bpm or more (26% 
> versus 16%, respectively). In a clinical trial in pediatric patients 
> aged 12 years and older with normal baseline heart rate, more 
> patients treated with WEGOVY<sup>®</sup> injection compared to placebo had 
> maximum changes in heart rate of 20 bpm or more (54% versus 
> 39%) [see Adverse Reactions (6.1)]. Findings were similar in a trial 
> with the WEGOVY<sup>®</sup> tablets.
> Monitor heart rate at regular intervals consistent with usual clinical 
> practice. Instruct patients to inform their healthcare providers of 
> palpitations or feelings of a racing heartbeat while at rest during 
> WEGOVY<sup>®</sup> treatment. If patients experience a sustained increase 
> in resting heart rate, discontinue WEGOVY<sup>®</sup>.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-boxed-warning-thyroid"></a>

### Does Wegovy cause thyroid cancer (boxed warning)?

> “WARNING: RISK OF THYROID C−CELL TUMORS
> •	In rodents, semaglutide causes dose-dependent 
> and treatment-duration-dependent thyroid C-cell 
> tumors at clinically relevant exposures. It is 
> unknown whether WEGOVY<sup>®</sup> causes thyroid C-cell 
> tumors, including medullary thyroid carcinoma 
> (MTC), in humans as human relevance of 
> semaglutide-induced rodent thyroid C-cell tumors 
> has not been determined [see Warnings and 
> Precautions (5.1), Nonclinical Toxicology (13.1)].
> •	WEGOVY<sup>®</sup> is contraindicated in patients with a 
> personal or family history of MTC or in patients 
> with Multiple Endocrine Neoplasia syndrome 
> type 2 (MEN 2) [see Contraindications (4)]. 
> Counsel patients regarding the potential risk 
> for MTC with the use of WEGOVY<sup>®</sup> and inform 
> them of symptoms of thyroid tumors (e.g., 
> a mass in the neck, dysphagia, dyspnea, 
> persistent hoarseness). Routine monitoring of 
> serum calcitonin or using thyroid ultrasound 
> is of uncertain value for early detection of 
> MTC in patients treated with WEGOVY<sup>®</sup> [see 
> Contraindications (4), Warnings and Precautions 
> (5.1)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

> “Cases of MTC in patients treated with liraglutide, another GLP-1 
> receptor agonist, have been reported in the postmarketing period; 
> the data in these reports are insufficient to establish or exclude 
> a causal relationship between MTC and GLP-1 receptor agonist 
> use in humans.
> WEGOVY<sup>®</sup> is contraindicated in patients with a personal or 
> family history of MTC or in patients with MEN 2. Counsel patients 
> regarding the potential risk for MTC with the use of WEGOVY<sup>®</sup> and 
> inform them of symptoms of thyroid tumors (e.g., a mass in the 
> neck, dysphagia, dyspnea, persistent hoarseness).
> Routine monitoring of serum calcitonin or using thyroid ultrasound 
> is of uncertain value for early detection of MTC in patients treated 
> with WEGOVY<sup>®</sup>. Such monitoring may increase the risk of 
> unnecessary procedures, due to the low-test specificity for serum 
> calcitonin and a high background incidence of thyroid disease. 
> Significantly elevated serum calcitonin value may indicate MTC and 
> patients with MTC usually have calcitonin values greater than 50 
> ng/L. If serum calcitonin is measured and found to be elevated, the 
> patient should be further evaluated. Patients with thyroid nodules 
> noted on physical examination or neck imaging should also be 
> further evaluated.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-contraindications"></a>

### Who should not take Wegovy?

> “WEGOVY<sup>®</sup> is contraindicated in the following conditions:
> •	A personal or family history of MTC or in patients with MEN 2 
> [see Warnings and Precautions (5.1)].
> •	A prior serious hypersensitivity reaction to semaglutide or 
> to any of the excipients in WEGOVY<sup>®</sup> injection or WEGOVY<sup>®</sup> 
> tablet. Serious hypersensitivity reactions, including 
> anaphylaxis and angioedema, have been reported with 
> WEGOVY<sup>®</sup> [see Warnings and Precautions (5.7)].”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-pancreatitis"></a>

### Can Wegovy cause pancreatitis?

> “Acute pancreatitis, including fatal and non-fatal hemorrhagic or 
> necrotizing pancreatitis, has been observed in patients treated 
> with GLP-1 receptor agonists, including WEGOVY<sup>®</sup> [see Adverse 
> Reactions (6)]. After initiation of WEGOVY<sup>®</sup>, observe patients 
> carefully for signs and symptoms of acute pancreatitis, which may 
> include persistent or severe abdominal pain (sometimes radiating 
> to the back), and which may or may not be accompanied by nausea 
> or vomiting. If pancreatitis is suspected, discontinue WEGOVY<sup>®</sup> 
> and initiate appropriate management.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

> “In WEGOVY<sup>®</sup> clinical trials in adults for weight reduction, acute 
> pancreatitis was confirmed by adjudication in 4 WEGOVY<sup>®</sup>-treated 
> patients (0.2 cases per 100 patient years) and 1 in placebo-treated 
> patients (less than 0.1 cases per 100 patient years). One additional 
> case of acute pancreatitis was confirmed in a patient treated with 
> WEGOVY<sup>®</sup> in another clinical trial.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “Adult and pediatric patients treated with WEGOVY<sup>®</sup> had a mean 
> increase from baseline in amylase of 15% to 16% and lipase of 
> 39% in clinical trials for weight reduction. These changes were 
> not observed in the placebo group.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “The clinical significance of 
> elevations in lipase or amylase with WEGOVY<sup>®</sup> is unknown in the 
> absence of other signs and symptoms of pancreatitis.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-gallbladder"></a>

### Can Wegovy cause gallstones or gallbladder problems?

> “Treatment with WEGOVY<sup>®</sup> is associated with an increased 
> occurrence of cholelithiasis and cholecystitis. The incidence of 
> cholelithiasis and cholecystitis was higher in WEGOVY<sup>®</sup> injection-
> treated pediatric patients aged 12 years and older than in WEGOVY<sup>®</sup> 
> injection-treated adults. In randomized clinical trials in adults for 
> weight reduction, cholelithiasis was reported by 1.6% of WEGOVY<sup>®</sup> 
> injection-treated patients and 0.7% of placebo injection-treated 
> patients, and by 2.5% of WEGOVY<sup>®</sup> tablet-treated patients and 
> 1% of placebo tablet-treated patients. Cholecystitis was reported 
> by 0.6% of WEGOVY<sup>®</sup> injection-treated adult patients and 0.2% 
> of placebo- treated patients. In a clinical trial in pediatric patients 
> aged 12 years and older for weight reduction, cholelithiasis was 
> reported by 3.8% of WEGOVY<sup>®</sup> injection-treated patients and 0% 
> placebo-treated patients. Cholecystitis was reported by 0.8% of 
> WEGOVY<sup>®</sup> injection-treated pediatric patients and 0% placebo-
> treated patients [see Adverse Reactions (6.1)].
> Substantial or rapid weight loss can increase the risk of 
> cholelithiasis; however, the incidence of acute gallbladder disease 
> was greater in WEGOVY<sup>®</sup>-treated patients than in placebo-treated 
> patients, even after accounting for the degree of weight loss. If 
> cholelithiasis is suspected, gallbladder studies and appropriate 
> clinical follow-up are indicated.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-hypoglycemia"></a>

### Can Wegovy cause low blood sugar (hypoglycemia)?

> “WEGOVY<sup>®</sup> lowers blood glucose and can cause hypoglycemia.
> In a trial of WEGOVY<sup>®</sup> injection in adult patients with type 2 diabetes 
> and body mass index (BMI) greater than or equal to 27 kg/m<sup>2</sup> for 
> weight reduction (Study 3), hypoglycemia (defined as a plasma 
> glucose less than 54 mg/dL) was reported in more patients treated 
> with WEGOVY<sup>®</sup> versus placebo [see Adverse Reactions (6.1)]. One 
> episode of severe hypoglycemia (requiring the assistance of another 
> person) was reported in one WEGOVY<sup>®</sup> treated patient versus no 
> placebo-treated patients [see Clinical Studies (14.2)].
> In glycemic control clinical trials, the risk of hypoglycemia 
> was increased when semaglutide injection or tablet was used 
> concomitantly with insulin or an insulin secretagogue (e.g., 
> sulfonylurea). Patients with diabetes mellitus taking WEGOVY<sup>®</sup> in 
> combination with insulin or an insulin secretagogue may have an 
> increased risk of hypoglycemia, including severe hypoglycemia. 
> The use of WEGOVY<sup>®</sup> in patients with type 1 diabetes mellitus or 
> in combination with insulin has not been evaluated.
> Inform patients of the risk of hypoglycemia and educate them 
> on the signs and symptoms of hypoglycemia. In patients with 
> diabetes, monitor blood glucose prior to starting WEGOVY<sup>®</sup> 
> and during WEGOVY<sup>®</sup> treatment. When initiating WEGOVY<sup>®</sup>, 
> consider reducing the dose of concomitantly administered insulin 
> or insulin secretagogue to reduce the risk of hypoglycemia [see 
> Drug Interactions (7.1)].”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

> “In a trial of adult patients with type 2 diabetes and BMI greater 
> than or equal to 27 kg/m<sup>2</sup> for weight reduction, clinically 
> significant hypoglycemia (defined as a plasma glucose less than 
> 54 mg/dL) was reported in 6.2% of WEGOVY<sup>®</sup> injection-treated 
> patients versus 2.5% of placebo-treated patients. A higher rate of 
> clinically significant hypoglycemic episodes was reported with 
> WEGOVY<sup>®</sup> injection (semaglutide 2.4 mg) versus semaglutide 
> 1 mg injection (10.7 vs. 7.2 episodes per 100 patient years of 
> exposure, respectively); the rate in the placebo-treated group was 
> 3.2 episodes per 100 patient years of exposure. In addition, one 
> episode of severe hypoglycemia requiring intravenous glucose was 
> reported in a WEGOVY<sup>®</sup> injection-treated patient versus none in 
> placebo-treated patients. The risk of hypoglycemia was increased 
> when WEGOVY<sup>®</sup> was used with a sulfonylurea.”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “Episodes of hypoglycemia have been reported with GLP-1 receptor 
> agonists in adult patients without type 2 diabetes mellitus. In 
> WEGOVY<sup>®</sup> clinical trials in adult patients without type 2 diabetes 
> mellitus for weight reduction, there was no systematic capturing 
> or reporting of hypoglycemia.
> In a CV outcomes trial in adult patients without type 2 diabetes, 
> 3 episodes of serious hypoglycemia were reported in WEGOVY<sup>®</sup> 
> injection-treated patients versus 1 episode in placebo. Patients 
> with a history of bariatric surgery (a risk factor for hypoglycemia) 
> had more events of serious hypoglycemia while taking WEGOVY<sup>®</sup> 
> injection (2.3%, 2/87) than placebo (0%, 0/97).”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-kidney-injury"></a>

### Can Wegovy cause kidney problems?

> “There have been postmarketing reports of acute kidney injury, 
> in some cases requiring hemodialysis, in patients treated 
> with semaglutide [see Adverse Reactions (6)]. The majority 
> of the reported events occurred in patients who experienced 
> gastrointestinal adverse reactions leading to dehydration such as 
> nausea, vomiting, or diarrhea [see Adverse Reactions (6)].
> Monitor renal function in patients reporting adverse reactions to 
> WEGOVY<sup>®</sup> that could lead to volume depletion, especially during 
> dosage initiation and escalation of WEGOVY<sup>®</sup>.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

> “Acute kidney injury occurred in clinical trials for weight reduction 
> in 7 adult patients (0.4 cases per 100 patient years) receiving 
> WEGOVY<sup>®</sup> versus 4 patients (0.2 cases per 100 patient years of 
> exposure) receiving placebo. Some of these adverse reactions 
> occurred in association with gastrointestinal adverse reactions 
> or dehydration. In addition, 2 patients treated with WEGOVY<sup>®</sup> had 
> acute kidney injury with dehydration in other clinical trials. The 
> risk of renal adverse reactions with WEGOVY<sup>®</sup> was increased in 
> adult patients with a history of renal impairment (trials included 
> 65 patients with a history of moderate or severe renal impairment 
> at baseline), and occurred more frequently during dose titration.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

<a id="wegovy-surgery-anesthesia"></a>

### Should Wegovy be stopped before surgery or anesthesia?

> “WEGOVY<sup>®</sup> delays gastric emptying [see Clinical Pharmacology 
> (12.2)]. There have been rare postmarketing reports of pulmonary 
> aspiration in patients receiving GLP-1 receptor agonists undergoing 
> elective surgeries or procedures requiring general anesthesia or 
> deep sedation who had residual gastric contents despite reported 
> adherence to preoperative fasting recommendations.
> Available data are insufficient to inform recommendations to 
> mitigate the risk of pulmonary aspiration during general anesthesia 
> or deep sedation in patients taking WEGOVY<sup>®</sup>, including whether 
> modifying preoperative fasting recommendations or temporarily 
> discontinuing WEGOVY<sup>®</sup> could reduce the incidence of retained 
> gastric contents. Instruct patients to inform healthcare providers 
> prior to any planned surgeries or procedures if they are taking 
> WEGOVY<sup>®</sup>.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-allergic-reactions"></a>

### Can Wegovy cause allergic reactions?

> “Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) 
> have been reported with WEGOVY<sup>®</sup>. If hypersensitivity reactions 
> occur, discontinue use of WEGOVY<sup>®</sup>, treat promptly per standard 
> of care, and monitor until signs and symptoms resolve. WEGOVY<sup>®</sup> 
> is contraindicated in patients with a prior serious hypersensitivity 
> reaction to semaglutide or to any of the excipients in WEGOVY<sup>®</sup> 
> [see Adverse Reactions (6.2)].
> Anaphylaxis and angioedema have been reported with other 
> GLP-1 receptor agonists. Use caution in a patient with a history of 
> anaphylaxis or angioedema with another GLP-1 receptor agonist 
> because it is unknown whether such patients will be predisposed 
> to these reactions with WEGOVY<sup>®</sup>.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-diabetic-retinopathy"></a>

### Can Wegovy worsen diabetic retinopathy?

> “In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly 
> injection in adult patients with type 2 diabetes and high CV risk, 
> diabetic retinopathy complications (which was a 4-component 
> adjudicated endpoint) occurred in patients treated with semaglutide 
> injection (3%) compared to placebo (1.8%). The absolute risk 
> increase for diabetic retinopathy complications was larger 
> among patients with a history of diabetic retinopathy at baseline 
> (semaglutide injection 8.2%, placebo 5.2%) than among patients 
> without a known history of diabetic retinopathy (semaglutide 
> injection 0.7%, placebo 0.4%).
> In a trial of adult patients with type 2 diabetes and BMI greater 
> than or equal to 27 kg/m<sup>2</sup> for weight reduction (Study 3), diabetic 
> retinopathy was reported by 4% of WEGOVY<sup>®</sup> injection-treated 
> patients and 2.7% placebo-treated patients [see Clinical Studies 
> (14.2)].
> In a glycemic control trial evaluating a dose comparable to the 9 
> mg dose and the 25 mg semaglutide tablet dose in patients with 
> type 2 diabetes, a similar proportion of patients in each dose group 
> reported diabetic retinopathy related adverse reactions during the 
> trial; 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide 
> group, respectively, reported moderate-severe non-proliferative 
> diabetic retinopathy events, and 0% and 0.4% reported proliferative 
> retinopathy events, respectively.
> Rapid improvement in glucose control has been associated 
> with a temporary worsening of diabetic retinopathy. The effect 
> of long-term glycemic control with semaglutide on diabetic 
> retinopathy complications has not been studied. Patients with a 
> history of diabetic retinopathy should be monitored for progression 
> of diabetic retinopathy.”

Source: [WEGOVY: Prescribing information, page 4, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=4)

<a id="wegovy-overdose"></a>

### What should be done after a Wegovy overdose?

> “Overdoses have been reported with other GLP-1 receptor agonists. Effects have included severe 
> nausea, severe vomiting, and severe hypoglycemia. In the event of overdose, appropriate supportive 
> treatment should be initiated according to the patient’s clinical signs and symptoms. In the event 
> of an overdose of WEGOVY<sup>®</sup>, consider contacting the Poison Help line (1-800-222-1222) or a”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “medical toxicologist for additional overdosage management recommendations. A prolonged period 
> of observation and treatment for these symptoms may be necessary, taking into account the long 
> half-life of WEGOVY<sup>®</sup> of approximately 1 week.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

Note: The OVERDOSAGE section starts on page 7 of the Prescribing Information and continues on page 8.

## Side effects

<a id="wegovy-antibodies"></a>

### Do antibodies to Wegovy affect how well it works?

> “During the 68-week treatment periods in Studies 2 and 3 in adults [see Clinical Studies (14.2)], 
> 50/1709 (3%) of patients treated with WEGOVY<sup>®</sup> 2.4 mg injection developed anti-semaglutide 
> antibodies (referred to as anti-drug-antibodies or ADA).”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “Using a new assay, 202/1311 (15.4%) of patients 
> treated with WEGOVY<sup>®</sup> 7.2 mg injection and 34/304 (11.2%) of patients treated with WEGOVY<sup>®</sup> 2.4 
> mg injection developed anti-semaglutide antibodies during 72-week treatment periods in Studies 8 
> and 9. A total of 36 (17.8% of 202 patients treated with WEGOVY<sup>®</sup> 7.2 mg injection who tested ADA 
> positive) and 3 (8.8% of 34 patients treated with WEGOVY<sup>®</sup> 2.4 mg injection who tested ADA positive) 
> patients developed antibodies that cross reacted with native GLP-1 in Studies 8 and 9. The clinical 
> consequences of antibodies that cross react with native GLP-1 are unknown.”

Source: [WEGOVY: Prescribing information, page 9, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=9)

> “No identified clinically significant effect of ADA on pharmacokinetics for WEGOVY<sup>®</sup> injection was 
> observed.
> There is insufficient evidence to characterize the effects of ADA on pharmacodynamics, safety, or 
> effectiveness of WEGOVY<sup>®</sup>.”

Source: [WEGOVY: Prescribing information, page 9, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=9)

> “In adult clinical trials for weight reduction, allergic reactions 
> occurred in 16% (8/50) of WEGOVY<sup>®</sup>-treated patients with anti-
> semaglutide antibodies and in 7% (114/1659) of WEGOVY<sup>®</sup>-treated 
> patients who did not develop anti-semaglutide antibodies [see 
> Clinical Pharmacology (12.6)].”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

## Related pages
- [Medical information: Wegovy (semaglutide): All indications](https://www.evicenter.com/medical-information/wegovy)
- [Indication](https://www.evicenter.com/medical-information/wegovy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/wegovy/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/wegovy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/wegovy/storage-and-supply)
